Better Clinical Trial Safety Data Would Aid Benefit/Risk Analysis – DIA Europe Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
More work needs to be done on benefit/risk assessments before Phase II/III, industry reps say.